Trabectedin and its potential in the treatment of soft tissue sarcoma

Therapeutics and Clinical Risk Management

Volumn 4, Issue 1, 2008, Pages 109-116

  Cassier, Philippe A ^a   Dufresne, Armelle ^a   Blay, Jean Yves ^a,b   Fayette, Jérôme ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE LÉON BÉRARD   (France)

Author keywords

Chemotherapy; DNA repair; Drug development; Sarcoma

Indexed keywords

BRCA1 PROTEIN; CAPECITABINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; IFOSFAMIDE; IMATINIB; PACLITAXEL; RNA BINDING PROTEIN; SEROTONIN 3 ANTAGONIST; STEROID; TRABECTEDIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EWING SARCOMA; EXCISION REPAIR; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERBILIRUBINEMIA; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER TOXICITY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; VOMITING;

EID: 41549138731     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Antman K, Crowley J, Balcerzak SP, et al. 1993. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol, 11:1276-85.
2. Antonescu CR, Tschernyavsky SJ, Decuseara R, et al. 2001. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res, 7:3977-87.
3. Bay JO, Ray-Coquard I, Fayette J, et al. 2006. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer, 119:706-11.
4. Blay JY, Le CA, Verweij J, Scurr M, et al. (2004). A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. Eur J Cancer, 40:1327-31.
5. Clark MA, Fisher C, Judson I, et al. 2005. Soft-tissue sarcomas in adults. N Engl J Med, 353:701-11.
6. Cohen RB, Schilder RJ, Cheng J, et al. 2005. Final results of a combination study between trabectedin and pegylated. ASCO Meeting Abstracts, 23:3074.
7. Crozat A, Aman P, Mandahl N, et al. 1993. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature, 363:640-4.
8. D'Incalci M, Colombo T, Ubezio P, et al. 2003. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer, 39:1920-6.
9. David-Cordonnier MK Gajate C, Olmea O, et al. 2005. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol, 12:1201-10.
10. Delaloge S, Yovine A, Taamma A, et al. 2001. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients - preliminary evidence of activity. J Clin Oncol, 19:1248-55.
11. Donald S, Verschoyle RD, Greaves P, et al. 2003. Complete protection by high-dose dexamethasone against the hepatotoxicity ofthe novel antitumor drug yondelis (ET-743) in the rat. Cancer Res, 63:5902-8.
12. Edmonson JH, Ryan LM, Blum RH, et al. 1993. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol, 11:1269-75.
13. Friedman D, Hu Z, Kolb EA, et al. 2002. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res, 62:3377-81.
14. Garcia-Carbonero R, Supko JG, Maki RG, et al. 2005. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol, 23:5484-92.
15. Garcia-Carbonero R, Supko JG, Manola J, et al. 2004. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol, 22:1480-90.
16. Gomez J, Lopez-Lazaro L, Guzman C, et al. 2000. Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. ASCO Meeting Abstracts, 19:727.
17. Gore L, Rivera E, Lavallee K, et al. 2006. Phase I combination study of trabectedin (T) and capecitabine (C) in patients with advanced malignancies. ASCO Meeting Abstracts, 24:2079.
18. Grasselli G, Malossi A, Colombo N, et al. 2007. Phase I and pharmacokinetic (PK) study of ecteinascidin-743 (ET, Trabectedin) and cisplatin (P) combination in pre-treated patients (pts) with selected advanced solid tumors. ASCO Meeting Abstracts, 22:542.
19. Grosso F, Demetri GD, Blay JY, et al. 2006. Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas. ASCO Meeting Abstracts, 24:9511.
20. Grosso F, Dileo P, Sanfilippo R, et al. 2006. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer, 42:1484-90.
21. Grosso F, Forni C, Frapolli R, et al. 2007). Sensitivity of myxoid-round cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcript. ASCO Meeting Abstracts, 25: 10000.
22. Grosso F, Jones RL, Demetri GD, et al. 2007. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol, 8:595-602.
23. Hensley ML, Maki R, Venkatraman E, et al. 2002. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol, 20:2824-31.
24. Herrero AB, Martin-Castellanos C, Marco E, et al. 2006. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res, 66:8155-62.
25. Huygh G, Clement PM, Dumez H, et al. 2006. Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma, 2006:56282.
26. Blay JY, Judson I, et al. 2005, Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol, 23:576-84.
27. Morgan JA, Le Cesne A, Chawla S, et al. 2007. Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I). ASCO Meeting Abstracts, 25:10060.
28. Papadopoulos KP, Chu Q, Patnaik A, et al. 2006. Phase I and pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. ASCO Meeting Abstracts, 24:2029.
29. Patel SR, Gandhi V, Jenkins J, et al. 2001. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation.. J Clin Oncol, 19:3493-9.
30. Ryan DP, Puchalski T, Supko JG, et al. 2002. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist, 7:531-8.
31. Ryan DP, Supko JG, Eder JP, et al. 2001. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res, 7:231-42.
32. Samuels BL, Rushing D, Chawla SP, et al. 2004. Randomized phase II study of trabectedin (ET-743) given by two. ASCO Meeting Abstracts, 22:9000.
33. Schoffski P, Casali PG, Taron M, et al. 2006. DNA repair functionality modulates the clinical outcome of patients. ASCO Meeting Abstracts, 24:9522.
34. Soares DG, Escargueil AE, Poindessous V, et al. 2007. From the cover: replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci USA, 104:13062-7.
35. Taamma A, Misset JL, Riofrio M, et al. 2001. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol, 19:1256-65.
36. Takahashi N, Li W, Banerjee D, et al. 2002. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res, 62:6909-15.
37. Takahashi N, Li WW, Banerjee D, et al. 2001. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res, 7:3251-7.
38. Takebayashi Y, Goldwasser F, Urasaki Y, et al. 2001. Ecteinascidin 743 induces protein-linked. DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res, 7:185-91.
39. Takebayashi Y, Pourquier P, Zimonjic DB, et al. 2001. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med, 7:961-66.
40. Twelves C, Hoekman K, Bowman A, et al. 2003. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer, 39:1842-51.
41. Villalona-Calero MA, Eckhardt SG, Weiss G, et al. 2002. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res, 8:75-85.
42. Von Mehren M, Buck D, Temmer E, et al. 2006. Phase I study of trabectedin (T) in combination with docetaxel (D) in patients with advanced malignancies. ASCO Meeting Abstracts, 24:2068.
43. Wilson RE, Wood WC, Lerner HL, et al. 1986. Doxorubicin chemotherapy in the treatment of soft-tissue sarcoma. Combined results of two randomized trials. Arch Surg, 121:1354-9.
44. Yovine A, Riofrio M, Blay JY, et al. 2004. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol, 22:890-9.